EUVIMEDEUVIMED entdecken
ValidierungsstudieMultizentrische StudieOpen Access · CC BY 4.0

External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors

Juan Morote, Ángel Borque-Fernando, Luis M Esteban, Natàlia Picola, Jesús Muñoz-Rodriguez, Nahuel Paesano, Xavier Ruiz-Plazas, Marta V Muñoz-Rivero, Ana Celma, Gemma García-de Manuel, Berta Miró, José M Abascal und 1 weitere

World Journal of Urology · 10.07.2024 · 42 (1)

DOI: 10.1007/s00345-024-05092-0 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift World Journal of Urology, online erschienen am 10.07.2024. Verfasst von Juan Morote und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Vall d´Hebron Hospital, Barcelona, Spain. juan.morote@vallhebron.cat. Hauptthemen laut MEDLINE: Prostatic Neoplasms, 5-alpha Reductase Inhibitors, Magnetic Resonance Imaging, Predictive Value of Tests. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat Autònoma de Barcelona.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). Materials and methods A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2.

Results

The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783–0.842) and 0.849 (0.806–0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users.

Conclusions

The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms5-alpha Reductase InhibitorsMagnetic Resonance ImagingPredictive Value of TestsHumansMaleAgedMiddle AgedRetrospective StudiesSpainMultiparametric Magnetic Resonance Imaging

Stichwörter der Autor:innen

5-alpha reductase inhibitorPredictive modelRisk calculatorSignificant prostate cancerValidation

Substanzen

5-alpha Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Vall d´Hebron Hospital, Barcelona, Spain. juan.morote@vallhebron.cat.
  • Department of Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain. juan.morote@vallhebron.cat.
  • Department of Urology, Hospital Universitario Miguel Servet, IIS-Aragon, Zaragoza, Spain.
  • Department of Applied Mathematics, Escuela Universitaria Politécnica La Almunia, Universidad de Zaragoza, Zaragoza, Spain.
  • Department of Urology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.
  • Department of Urology, Hospital Universitari Parc Taulí, Sabadell, Spain.

Förderung

  • Universitat Autònoma de Barcelona

Zitieren

APA

Morote, J., Borque-Fernando, Á., Esteban, L. M., Picola, N., Muñoz-Rodriguez, J., Paesano, N., Ruiz-Plazas, X., Muñoz-Rivero, M. V., Celma, A., Manuel, G. G., Miró, B., Abascal, J. M., & Servian, P. (2024). External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors. World Journal of Urology, 42(1). https://doi.org/10.1007/s00345-024-05092-0

Vancouver

Morote J, Borque-Fernando Á, Esteban LM, Picola N, Muñoz-Rodriguez J, Paesano N, et al. External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors. World Journal of Urology. 2024;42(1). doi:10.1007/s00345-024-05092-0

BibTeX
@article{Morote2024,
  author = {Morote, Juan and Borque-Fernando, Ángel and Esteban, Luis M and Picola, Natàlia and Muñoz-Rodriguez, Jesús and Paesano, Nahuel and Ruiz-Plazas, Xavier and Muñoz-Rivero, Marta V and Celma, Ana and Manuel, Gemma García-de and Miró, Berta and Abascal, José M and Servian, Pol},
  title = {External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors},
  journal = {World Journal of Urology},
  year = {2024},
  volume = {42},
  number = {1},
  doi = {10.1007/s00345-024-05092-0}
}
Kostenlos starten →